1. Home
  2. WHWK vs CNTB Comparison

WHWK vs CNTB Comparison

Compare WHWK & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WHWK
  • CNTB
  • Stock Information
  • Founded
  • WHWK 2007
  • CNTB 2012
  • Country
  • WHWK United States
  • CNTB United States
  • Employees
  • WHWK N/A
  • CNTB N/A
  • Industry
  • WHWK Biotechnology: Pharmaceutical Preparations
  • CNTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • WHWK Health Care
  • CNTB Health Care
  • Exchange
  • WHWK Nasdaq
  • CNTB Nasdaq
  • Market Cap
  • WHWK 48.3M
  • CNTB 43.2M
  • IPO Year
  • WHWK N/A
  • CNTB 2021
  • Fundamental
  • Price
  • WHWK $1.69
  • CNTB $0.84
  • Analyst Decision
  • WHWK
  • CNTB Strong Buy
  • Analyst Count
  • WHWK 0
  • CNTB 1
  • Target Price
  • WHWK N/A
  • CNTB $8.00
  • AVG Volume (30 Days)
  • WHWK 143.2K
  • CNTB 76.4K
  • Earning Date
  • WHWK 05-08-2025
  • CNTB 05-15-2025
  • Dividend Yield
  • WHWK N/A
  • CNTB N/A
  • EPS Growth
  • WHWK N/A
  • CNTB N/A
  • EPS
  • WHWK 0.91
  • CNTB N/A
  • Revenue
  • WHWK $27,775,000.00
  • CNTB $26,033,000.00
  • Revenue This Year
  • WHWK $40.15
  • CNTB N/A
  • Revenue Next Year
  • WHWK N/A
  • CNTB N/A
  • P/E Ratio
  • WHWK $1.85
  • CNTB N/A
  • Revenue Growth
  • WHWK 16.51
  • CNTB 115.90
  • 52 Week Low
  • WHWK $1.21
  • CNTB $0.51
  • 52 Week High
  • WHWK $3.81
  • CNTB $2.07
  • Technical
  • Relative Strength Index (RSI)
  • WHWK N/A
  • CNTB 57.64
  • Support Level
  • WHWK N/A
  • CNTB $0.72
  • Resistance Level
  • WHWK N/A
  • CNTB $0.86
  • Average True Range (ATR)
  • WHWK 0.00
  • CNTB 0.07
  • MACD
  • WHWK 0.00
  • CNTB 0.00
  • Stochastic Oscillator
  • WHWK 0.00
  • CNTB 87.50

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Share on Social Networks: